Literature DB >> 4100034

Lupus-like syndrome induced by D-penicillamine in Wilson's disease.

J P Harpey, B Caille, R Moulias, J M Goust.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 4100034     DOI： 10.1016/s0140-6736(71)91022-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  15 in total

Review 1.  Penicillamine-induced arthropathy in Wilson's disease.

Authors:  J M Walshe; D N Golding
Journal:  Proc R Soc Med       Date:  1977

2.  Concomitant immune-related events in Wilson disease: implications for monitoring chelator therapy.

Authors:  Jessica Seessle; Daniel Nils Gotthardt; Mark Schäfer; Annina Gohdes; Jan Pfeiffenberger; Peter Ferenci; Wolfgang Stremmel; Karl Heinz Weiss
Journal:  J Inherit Metab Dis       Date:  2015-06-12       Impact factor: 4.982

Review 3.  Primary biliary cirrhosis associated with features of systemic lupus erythematosus.

Authors:  G D Iliffe; S Naidoo; T Hunter
Journal:  Dig Dis Sci       Date:  1982-03       Impact factor: 3.199

4.  Effect of penicillamine therapy on circulating immune complexes in rheumatoid arthritis.

Authors:  I Mohammed; D Barraclough; E J Holborow; B M Ansell
Journal:  Ann Rheum Dis       Date:  1975-10       Impact factor: 19.103

5.  Nephrotic syndrome induced by D-penicillamine therapy.

Authors:  P Jezersek; D Ferluga
Journal:  Int Urol Nephrol       Date:  1979       Impact factor: 2.370

6.  [Myasthenic syndrome during penicillamine treatment (author's transl)].

Authors:  F Schumm; M Stöhr
Journal:  Klin Wochenschr       Date:  1978-02-01

Review 7.  Penicillamine in rheumatoid arthritis. A problem of toxicity.

Authors:  H G Taylor; A Samanta
Journal:  Drug Saf       Date:  1992 Jan-Feb       Impact factor: 5.606

8.  D-penicillamine and immune complex deposition.

Authors:  J D Kirby; P A Dieppe; E C Huskisson; B Smith
Journal:  Ann Rheum Dis       Date:  1979-08       Impact factor: 19.103

9.  Polymyositis complicating D-penicillamine treatment.

Authors:  A O Aydintug; R Cervera; D D'Cruz; G Ramírez; R A Asherson; M A Khamashta; G R Hughes
Journal:  Postgrad Med J       Date:  1991-11       Impact factor: 2.401

Review 10.  Ocular myasthenia gravis after D-penicillamine administration.

Authors:  L J Katz; R L Lesser; J R Merikangas; J P Silverman
Journal:  Br J Ophthalmol       Date:  1989-12       Impact factor: 4.638
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.